Vous avez cherché: adrenoceptor (Maltais - Anglais)

dexmedetomidine hija agonista tal-alpha2-adrenoceptor.
dexmedetomidine is an alpha2-adrenoceptor agonist.

id-dexmedetomidina hija agonista tal-alpha2-adrenoceptor.
dexmedetomidine is an alpha2-adrenoceptor agonist.

mirabegron huwa beta 3-adrenoceptor agonist qawwi u selettiv.
mirabegron is a potent and selective beta 3-adrenoceptor agonist.

beta2-adrenoceptor agonist (iħalli effett fit-tul)
beta2-adrenoceptor agonist (long acting)

dexmedetomidine iwassal ukoll għal effetti oħra li huma α2-adrenoceptor mediated.
dexmedetomidine also induces a number of other α2-adrenoceptor mediated effects, which include piloerection, depression of motor and secretory functions of the gastrointestinal tract, diuresis and hyperglycaemia.

dexmedetomidine, l-ingredjent attiv ta' sileo, hu agonist ta' alpha-2 adrenoceptor.
dexmedetomidine, the active ingredient of sileo is an alpha-2 adrenoceptor agonist.

dexmedetomidine huwa α2-adrenoceptor agonist qawwi u selettiv li jimblokka l-ħruġ ta’ noradrenalina minn newroni noradrenerġiċi.
dexmedetomidine is a potent and selective α2-adrenoceptor agonist that inhibits the release of noradrenaline from noradrenergic neurons.

is- sustanza attiva f’ dexdomitor, dexmedetomidine, hija agonista ta ’ l - alpha2- adrenoceptor.
the active substance in dexdomitor, dexmedetomidine, is an alpha2-adrenoceptor agonist.

il- malformazzjonijiet kardjovaskulari osservati fil-fenek kienu jidhru li huma medjati permezz tal- attivazzjoni tal-beta 1-adrenoceptor.
the cardiovascular malformations observed in the rabbit were shown to be mediated via activation of the beta 1-adrenoceptor.

l-użu tal-alpha-1 adrenoceptor antagonist alfuzosin u sildenafil meta jintuża għall-kura ta’ pressjoni għolja arterjali pulmonari wkoll.
also the use of the alpha-1 adrenoceptor antagonist alfuzosin, and sildenafil when used for the treatment of pulmonary arterial hypertension.

antagonist α2–adrenoceptor speċifiku, atipamezole, li huwa approvat għall-użu f’annimali żgħar, intuża fin-nies biex jantagonizza l-effetti ta’ dexmedetomidine, b’mod sperimentali biss.
the specific α2 – adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans only experimentally to antagonize dexmedetomidine-induced effects.